Is AcelRx Pharmaceuticals Inc (ACRX) a Winner in the Drug Manufacturers - Specialty & Generic Industry?

Thursday, September 24, 2020 2:10 PM | InvestorsObserver Analysts

AcelRx Pharmaceuticals Inc (ACRX) is near the top in its industry group according to InvestorsObserver. ACRX gets an overall rating of 47. That means it scores higher than 47 percent of stocks. AcelRx Pharmaceuticals Inc gets a 82 rank in the Drug Manufacturers - Specialty & Generic industry. Drug Manufacturers - Specialty & Generic is number 139 out of 148 industries.

Overall Score - 47
ACRX has an Overall Score of 47. Find out what this means to you and get the rest of the rankings on ACRX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With AcelRx Pharmaceuticals Inc Stock Today?

AcelRx Pharmaceuticals Inc (ACRX) stock is flat -0.33% while the S&P 500 is up 1.11% as of 2:05 PM on Thursday, Sep 24. ACRX is flat $0.00 from the previous closing price of $1.53 on volume of 965,517 shares. Over the past year the S&P 500 is higher by 9.65% while ACRX is down -33.19%. ACRX lost -$0.62 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AcelRx Pharmaceuticals Inc (ACRX) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies